Hormonal
GLP-1 receptor agonists (GLP-1RAs) are perceived by current and past users as safe and effective for weight loss, with users strongly disagreeing that risks outweigh benefits, whereas non-users exhibit significant skepticism regarding safety and efficacy.
If you are considering GLP-1RAs, be aware that skepticism about safety and cost are common barriers, especially if you haven't used them. However, data from current and past users shows they strongly disagree that risks outweigh benefits and highly recommend the medication. Consult a healthcare provider to address specific safety concerns and cost barriers, as user experience often contradicts public skepticism.
Past and current users were less likely than non-users to express scepticism about safety and efficacy and 6.91 times more likely to strongly disagree (compared with being neutral) that ‘risks outweigh the benefits’... and 7.33 times more likely to strongly disagree... that ‘there is not enough evidence to suggest GLP-1RAs are safe’
Why this rating
Cross-sectional survey study; establishes perception and correlation, not causal efficacy or long-term safety outcomes.
Source
What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional survey study in the UK
Nadja Auerbach et al. · BMJ Public Health · 2025
DOI 10.1136/bmjph-2024-002519
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →